UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/566,389	10/566,389 05/26/2006 Abo		663073607	3744
25269 DYKEMA GOS	7590 12/26/200 SSETT PLLC	EXAMINER		
	QUARE, THIRD FLOO	FORTUNA, ANA M		
1300 I STREET WASHINGTO		ART UNIT	PAPER NUMBER	
			1797	
		MAIL DATE	DELIVERY MODE	
		12/26/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Astion Communication		Application	No.	Applicant(s)					
		10/566,389		AL-MAYAHI ET AL.					
Office Action Summary			Examiner		Art Unit				
			Ana M. Fortu	na	1797				
 Period for	The MAILING DATE of this commun Reply	ication appe	ears on the co	over sheet with the c	orrespondence ad	ddress			
WHICH - Extensi after SI - If NO p - Failure Any rep	RTENED STATUTORY PERIOD F IEVER IS LONGER, FROM THE M ons of time may be available under the provisions X (6) MONTHS from the mailing date of this comn eriod for reply is specified above, the maximum st to reply within the set or extended period for reply dy received by the Office later than three months a patent term adjustment. See 37 CFR 1.704(b).	IAILING DA of 37 CFR 1.136 nunication. atutory period will will, by statute, c	TE OF THIS S(a). In no event, Il apply and will excause the applicat	COMMUNICATION however, may a reply be tin pire SIX (6) MONTHS from ion to become ABANDONE	N. nely filed the mailing date of this of D (35 U.S.C. § 133).	·			
Status									
1) 5	Responsive to communication(s) file	ed on <i>24 No</i> v	vember 200	?					
·			action is non						
′=		<i>-</i> —			secution as to the	e merits is			
· —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
	n of Claims								
·		annlication							
•	Claim(s) <u>20-41</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
•	5) Claim(s) is/are allowed.								
	Claim(s) <u>20-41</u> is/are rejected.								
•	Claim(s) is/are objected to.	.4:	_14:	.:					
8)L C	Claim(s) are subject to restric	ction and/or (election requ	urement.					
Applicatio	n Papers								
9)☐ The specification is objected to by the Examiner.									
10) <u></u> ⊤I	ne drawing(s) filed on is/are:	a)∏ accep	pted or b)□	objected to by the I	Examiner.				
А	pplicant may not request that any obje	ction to the dr	rawing(s) be h	ield in abeyance. See	e 37 CFR 1.85(a).				
R	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority un	der 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notice (3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (Fition Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	PTO-948)	4) 5) 6)	=	ate				

Application/Control Number: 10/566,389 Page 2

Art Unit: 1797

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 20-33, 36-39, 40, 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 97/18166 (hereinafter WO '166) in view of Lefebvre (US 4,781,837) and Mickols (US 5,755,964). Publication WO'166 discloses a process for removing solvent, e.g. water, from saline water, such a brackish water, gray water, sea water etc. The process include the steps of disposing the solution to be treated at one side of a semi-permeable hydrophilic membrane, and disposing a second solution having a higher osmotic potential, e.g. salt brine (abstract, Figs. 1 and 6; page 3, lie 11-page 4, line 30). Solvent (water) passes across the membrane, diluting the second solution during the process; the second solution is further concentrated by removing water by reverse osmosis, electrodialysis, evaporation, or combination (abstract, step b). The membrane can be a thin film composite hydrophilic membrane in different

Art Unit: 1797

configurations (page. 11, third paragraph). The use of nanofiltration in the concentration step (b) is not disclosed in this reference (WO'166).

Patent '837 teaches combining osmotic separation using a concentrate salt solution and a hydrophobic membrane and concentration the diluted concentrate solution by a reverse osmosis membrane and recirculating the concentrate salt solution back to the process (abstract, column 2, lines 38-column 3, line 20; column 4-colum 5, line 26). Patent does not teach "nanofiltration", however, teaches the bases for membrane selection and membrane salt combination; the reference suggests the use of more open membranes to concentrate the osmotic (concentrate solution) that has been dilute and recycle back to the process; the membrane can have a larger pore size but has to be capable or retaining the large anion, or charged membrane capable of retaining hydrogen ions and anions of any size (column 11, lines 15-27).

Based on these teachings, it would have been obvious to one skilled in this art at the time this invention was made to substitute the reverse osmosis membrane in the process of WO'166, by a nanofiltration membrane, which is known to retain divalent salts from the high osmotic potential solution, or brine salt. It would have been obvious to one skilled in this art at the time the invention was made to predict the retention or magnesium sulfate or sodium sulfate, as in claim 7 of the present invention, by using a nanofiltration, base on the membrane retention of divalent ions.

Patent '964 is further cumulative and teaches use of nanofiltration membrane and its retention of divalent ions and organic compounds, such as glucose retention (column 1, lines 32-37, and column 3, lines 41-53). Further advantages of using nanofiltration, such

a high flux and lower pressure requirements are disclosed in this patent (column 2, second paragraph).

As to the pressure of operating of the nanofiltration membrane, the skilled in the art at the time this invention was made would have been motivated to adjust pressure based on requirements, e.g. depending on feed concentration, to be able to overcome the osmotic pressure, and maintain the pressure within the levels suggested by the manufactures of the membrane, to avoid membrane breakage.

It would have been further obvious to one skilled in this art at the time this invention was made to use nanofiltration membranes to concentrate the concentrate solution or high osmotic potential solution to reduce the pressure requirements during the concentration and increase flux, and more particularly to retaining any divalent ions present in the second solution, to produce water with an adjusted monovalent content as product from the nanofiltration stage.

As to claims 21, and 36-39, the nanofiltration pore size is lower than 10 nanometers (between RO and ultrafiltration) therefore the membrane will retain any particle having a size of 10 nanometers or greater. Regarding claim 41, the use of more than one nanofiltration membranes is considered to be cumulative.

As to claim 22, adjusting the amount of salt in the second solution to keep the higher osmotic potential, e.g to allow the diving force to direct the solvent across the membrane to the second solution is required in order to perform the solvent separation during the process.

Regarding claims 23-26, publication WO'166 teaches combining membrane concentration with evaporation (abstract, page 2, lines 27-34, and page 4, lines 15-30). The specific evaporation methods are not disclosed in WO'166, but are covered by the term "thermal evaporation (page 2, line 30).

Regarding claim 40, the term "up to" includes lower ranges of temperatures that includes zero. The temperature claimed can be assume to be ambient temperature, or can be temperatures generated by the salts addition.

It would have been obvious to one skilled in the art at the time this invention was made to select any of the conventional methods of thermal evaporation for concentrating to reach to higher concentrations of the osmotic solution, based on the suggestion of combining both, the membrane step and evaporation.

Claim 7 is discussed above. For claims 8-14, 19, the solvent in the first solution is water, as discussed above, and the solvent in the second solution is a "brine solution", containing divalent salts (page 3, lies 13-34).

3. Claims 34-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 97/18166 (hereinafter WO '166) in view of Lefebvre (US 4,781,837) and Mickols (US 5,755,964) as applied to claims1 above, and further in view of Herron et al (US 5,281,430). WO'166, '837, and '964 discussed above fail to disclose the antifouling agent or disinfectant in the second solution. Patent '430 teaches cleaning the membrane in an osmotic membrane separation process, by using antiscale or antifoaming agent, to remove residues from the membrane in the side where the osmotic agent is provided; Ultrasil (column 14, example 4). The patent does not provide

Application/Control Number: 10/566,389

Art Unit: 1797

the agent in the osmotic solution. The skilled in this art at the time this invention was made at the time this invention was made was able to predict the improvement in membrane cleaning by providing the agent (antifouling agent) within the concentrate solution, e.g cleaning the membrane in operation.

Page 6

4. Claims 20, 21, 22, 27, 27-28, 34-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yaeli (US 5,098,575) in view of Mickols (US 5,755,964) and further in view of Lefebvre (US4,782,837). Yaeli discloses a process of purifying seawater by combining natural osmosis and reverse osmosis, e.g. the step of concentration of the second solution is performed in a reverse osmosis membrane, which has inherent pore sized within the lower pore size range claimed in claims 2, and 17 (see abstract, figure, and column 3, lines 15 through column 4, line 44). Using a nanofiltration membrane in step b), to concentrate the dilute solution is not disclosed in the patent. Patent '964 discloses the properties of nanofiltration membranes and its divalent ion rejection, low pressure operation and high membrane flux as compared to the reverse osmosis membrane, as discussed in the paragraphs above. Patent '837, also discussed above teaches combining osmotic distillation and reverse osmosis and suggests using membranes of higher pore size to concentrate the osmotic solution containing magnesium sulfate, as discussed in the paragraphs above. It would have been obvious to one skilled in this art at the time this invention was made to substitute the reverse osmosis membrane in Yaeli, by a nanofiltration membrane, e.g. to increase the flux, reduce operational costs by reducing the pressure applied to the membrane separation,

and retain the osmotic agent in the osmotic solution, since nanofiltration membranes retain sugar molecules, in addition to divalent ions, as disclosed in '964.

As to claim 21, the retention of particles or components with sizes as claimed are inherent of the membrane, based on the nanofiltration membrane molecular weight cut-off. As to claims 23-25, concentrating the diluted second solution by evaporation is disclosed in patent '430, therefore, further combining reverse osmosis and evaporation to further concentrate the osmotic agent solution would have been obvious to the skilled artisan.

Response to arguments.

5. Applicant's arguments filed 11/24/08 have been fully considered but they are not persuasive. Claim 20 includes pressure limitations of "at least 7MPA. The later tem does not exclude higher pressures, as high as the temperatures used in reverse osmosis processes; and also includes ranges of low pressure which covers the suggested operating pressures for commercial nanofiltration membranes, the skilled in the art at the time this invention was made would have been motivated to adjust pressure based on requirements, e.g. depending on feed concentration, to be able to overcome the osmotic pressure, while maintaining the recommended operating pressures for the membrane. Patent US 6,508,936 s cited as evidence of operating pressures for NF, and teaches operating NF membranes at 70 bars (7Mpa). Applicant argues that monovalent salts are "preferred" in the prior art (WO'166), however, divalent salts are also suggested, and the invention is ot limited to preferred embodiments.

The species are directed to salts or sugars (see claim 26, such as magnesium salts and sucrose). The retention of multivalent ions by nanofiltration membranes is discussed in the office action, and well known in the art of desalination and water softening, which is supported by the references above. The skilled artisan at the time this invention was made can predict the rejection of these salts and/or sugars by nanofiltration, based on membrane pores size, inherent charge and selectivity. Applicant argues that in reference WO'166 the solution is reclaimed by reverse osmosis and that there is not disclosure of nanofiltration. Mickols teaches a membrane with the properties as in the membrane used in the current process and its performance for monovalent divalent salts separation, therefore, the retention of the salts used in the this process, which include divalent salts of magnesium, is predictable by the skilled artisan at the time this invention was made. Patent '837 does not mention "nanofiltration" by name, however, suggests selecting a membrane capable of retaining large ions, and charged membranes. The term "large ions" is assumed to be directed to multivalent ions, which are known to be retained by nanofiltration membranes. The membrane selection in the separation of the second solution is obviously determined based on the purity of the solution required and the particular salt and/or sugar recovered from the second solution. Reverse osmosis produces water of higher purity as compared to the water produced by nanofiltration, which permeates monovalent ions. It would have been obvious to one skilled artisan at the time this invention was made to tailor the process to recover water of a predetermined quality, or softened water by substituting

the reverse osmosis step by a nanofiltration step. The results when substituting the RO by a NF membrane can be predicted by the skilled artisan in terms of the membrane high rejection for divalent ions, and low retention of monovalent ions.

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, patent 5755964 provides motivation to use nanofiltration membrane for softening water at a faster rate due to the higher membrane flux as compared to nanofiltration membrane and the membrane separation of divalent ions, such as magnesium (column 1, lines 10-55).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ana M. Fortuna whose telephone number is (571) 272-1141. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David R. Sample can be reached on (571) 272-1376. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/566,389 Page 10

Art Unit: 1797

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ana Fortuna/ Primary Examiner, A. U. 1723

/Ana M Fortuna/

Primary Examiner, Art Unit 1797